F-1/A: Park Ha Biological Technology Files Amendment No. 3 to Form F-1 for IPO, Seeks Waiver on Financial Statement Age

Park Ha Biological Technology Co., Ltd. files an amendment to its Form F-1 registration statement for a proposed IPO and requests a waiver from the SEC regarding the age of its audited financial statements.

Summary

• Park Ha Biological Technology Co., Ltd., a Cayman Islands-based company, filed Amendment No. 3 to its Form F-1 registration statement with the SEC on November 6, 2024.
• The amendment includes updated exhibits and an exhibit index.
• The company is seeking to list its ordinary shares in the United States through an initial public offering (IPO).
• The company has requested a waiver from the SEC regarding Item 8.A.4 of Form 20-F, which requires audited financial statements to be no older than 12 months from the offering date for IPOs.
• Park Ha Biological Technology represents that it is not required to comply with this requirement in any other jurisdiction and that compliance is impracticable and involves undue hardship.
• The company's audited financial statements are as of October 31, 2023 and 2022, with unaudited interim financials as of April 30, 2024.
• The company anticipates its audited financial statements for the fiscal year ended October 31, 2024, will not be available until February 2025.
• The company commits to not seeking effectiveness of the registration statement if its audited financial statements are older than 15 months at the time of the IPO.

Sentiment

Score: 7

Explanation: The document is primarily procedural, relating to an IPO filing. The request for a waiver is a standard practice for foreign companies, so the sentiment is neutral to slightly positive as the company is moving forward with its listing plans.

Positives

• The company is actively pursuing an IPO in the United States.
• The company is transparently addressing potential regulatory hurdles related to financial reporting requirements.
• The company has secured consents from its independent registered public accounting firm (WWC, P.C.) and legal counsel for the registration statement.

Negatives

• The company requires a waiver from the SEC regarding the age of its audited financial statements, which could potentially delay the IPO process.
• The audited financial statements for the fiscal year ending October 31, 2024, are not expected to be available until February 2025, indicating a potential lag in financial reporting.

Risks

• The SEC may not grant the requested waiver, potentially delaying or complicating the IPO.
• Delays in obtaining audited financial statements could impact the timing of the IPO.
• The company's reliance on a waiver could raise concerns among investors regarding the timeliness of its financial reporting.

Future Outlook

The company intends to proceed with its IPO and listing in the United States, pending SEC review and approval of its registration statement and waiver request.

Management Comments

• The company represents to the Commission that it is not required by any jurisdiction outside the United States to prepare consolidated financial statements audited under any generally accepted auditing standards for any interim period.
• The company represents that full compliance with Item 8.A.4 of Form 20-F at present is impracticable and involves undue hardship for the Company.

Industry Context

The request for a waiver regarding the age of financial statements is not uncommon for foreign private issuers seeking to list in the U.S., as their reporting timelines may differ from U.S. domestic companies. The SEC often grants such waivers if the company can demonstrate undue hardship and that the information will be provided in a timely manner.

Comparison to Industry Standards

• Many foreign companies listing on US exchanges request waivers for the 12-month financial statement requirement, citing logistical challenges and differing reporting standards in their home countries.
• Companies like Alibaba and JD.com, when initially listing in the US, also navigated similar requirements related to financial reporting and compliance with US regulations.
• The SEC's Division of Corporation Finance provides guidance on international reporting and disclosure issues, indicating a willingness to grant waivers when appropriate, as long as investors are adequately protected.

Stakeholder Impact

• Shareholders: Potential for increased value if the IPO is successful.
• Employees: Potential for increased opportunities and benefits.
• Customers: No immediate impact expected.
• Suppliers: Potential for increased business volume.
• Creditors: Potential for improved creditworthiness.

Next Steps

• The company awaits the SEC's decision on its waiver request.
• The company will continue to prepare for its IPO, including finalizing the underwriting agreement and other related documents.
• The company will file further amendments to the registration statement as needed, including updated financial information.

Key Dates

Keywords

IPO, Form F-1, Registration Statement, Waiver Request, Financial Statements, Park Ha Biological Technology, SEC, Initial Public Offering, Audited Financials